Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.52 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.48 |
| ▸ | CDK11A | Q9UQ88 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726478 | 0.94 | CCNA2 (0.48) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5725347 | 0.92 | CCNT1 (0.57) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5726341 | 0.91 | DHODH (0.47) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5726886 | 0.91 | CCNA2 (0.48) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5725065 | 0.91 | CCNA2 (0.48) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5727340 | 0.88 | CCNT1 (0.55) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5725526 | 0.88 | CCNT1 (0.55) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5725845 | 0.83 | CCNA2 (0.44) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL5725825 | 0.83 | DHODH (0.52) | CCNA2CDK2CDK5CDK5R1DHODH | |
| SCHEMBL5726511 | 0.82 | CCNT1 (0.45) | CCNA2CDK2CCNT1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | CCNA2 24/4885CDK2 1/4885CCNT1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.